
    
      Patients with stage IV NSCLC who have EGFR exon 19 or 21 mutations will randomized to
      received oral erlotinib 150mg or gefitinib 250mg once daily until disease progression or
      unacceptable toxicity. Method of direct DNA sequencing of tumor tissue is used to analysis
      EGFR mutation status of exons 18-21. The response will be evaluated by RECIST criteria first
      month,second month and then repeat every 3 months after the beginning of the treatment weeks.
    
  